Myotilin, a New Topotecan Resistant Protein in Ovarian Cancer Cell Lines

肌收缩蛋白,卵巢癌细胞系中的一种新型拓扑替康耐药蛋白

阅读:6
作者:Karolina Sterzyńska, Andrzej Klejewski, Karolina Wojtowicz, Monika Świerczewska, Michał Nowicki, Jacek Brązert, Radosław Januchowski

Background

Low effectiveness of chemotherapy in ovarian cancer

Conclusion

Our results suggest that upregulation of MYOT can be related to TOP resistance in ovarian cancer cell lines.

Methods

We analyzed development of TOP resistance in ovarian cancer cell lines (A2780 and W1). On the base of our previous

Results

We observed increased expression of MYOT in TOP resistant cell lines at both mRNA and protein level. MYOT, together with extracellular matrix molecules like COL1A2 and COL15A1 were also secreted to corresponding cell culture media.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。